

09/830744

L Number	Hits	Search Text	DB	Time stamp
1	54180	polysaccharide	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:45
2	8944	polysaccharide and cross-link\$	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:46
3	1052	((polysaccharide and cross-link\$) and polyamine	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:47
4	328	((polysaccharide and cross-link\$) and polyamine) and carboxy	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:47
5	94	((polysaccharide and cross-link\$) and polyamine) and carboxy) and activate	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:49
6	6568	polysaccharide and carboxy	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:48
7	2134	(polysaccharide and carboxy) and cross-link\$	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:48
8	476	((polysaccharide and carboxy) and cross-link\$) and (diamine or triamine)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:49
9	0	((polysaccharide and carboxy) and cross-link\$) and (diamine or triamine)) and hyaluronic14 and activate	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:50
10	80	((polysaccharide and carboxy) and cross-link\$) and (diamine or triamine)) and hyaluronic	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 13:50
11	67	((polysaccharide and carboxy) and cross-link\$) and (diamine or triamine)) and chitin	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:18
12	535	536/21	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:18
13	94	536/21 and cross-link\$	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:18
14	27	(536/21 and cross-link\$) and hyaluronic	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:18

15	6	((536/21 and cross-link\$) and hyaluronic) and (diamine or polyamine)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:22
16	2833	514/54	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:23
17	522	514/54 and cross-link\$	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:23
18	192	(514/54 and cross-link\$) and hyaluronic	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:23
19	24	((514/54 and cross-link\$) and hyaluronic) and (diamine or polyamine)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:23

L Number	Hits	Search Text	DB	Time stamp
1	54180	polysaccharide	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 13:45
2	8944	polysaccharide and cross-link\$	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 13:46
3	1052	(polysaccharide and cross-link\$) and polyamine	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 13:47
4	328	((polysaccharide and cross-link\$) and polyamine) and carboxy	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 13:47
5	94	((polysaccharide and cross-link\$) and polyamine) and carboxy) and activate	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 13:49
6	6568	polysaccharide and carboxy	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 13:48
7	2134	(polysaccharide and carboxy) and cross-link\$	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 13:48
8	476	((polysaccharide and carboxy) and cross-link\$) and (diamine or triamine)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 13:49
9	0	((polysaccharide and carboxy) and cross-link\$) and (diamine or triamine)) and hyaluronicl4 and activate	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 13:50
10	80	((polysaccharide and carboxy) and cross-link\$) and (diamine or triamine)) and hyaluronic	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 13:50
11	67	((polysaccharide and carboxy) and cross-link\$) and (diamine or triamine)) and chitin	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 14:18
12	535	536/21	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 14:18
13	94	536/21 and cross-link\$	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 14:18
14	27	(536/21 and cross-link\$) and hyaluronic	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2002/09/23 14:18

15	6	((536/21 and cross-link\$) and hyaluronic) and (diamine or polyamine)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:22
16	2833	514/54	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:23
17	522	514/54 and cross-link\$	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:23
18	192	(514/54 and cross-link\$) and hyaluronic	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:23
19	24	((514/54 and cross-link\$) and hyaluronic) and (diamine or polyamine)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:49
20	0	((514/54 and cross-link\$) and hyaluronic) and (diamine or polyamine)) and complex?	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:49
21	130	((514/54 and cross-link\$) and hyaluronic) and comple?	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:50
22	57	((514/54 and cross-link\$) and hyaluronic) and comple?) and (copper or iron)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:52
23	76	((((polysaccharide and carboxy) and cross-link\$) and (diamine or triamine)) and hyaluronic) and (copper or iron or metal or ion)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:58
24	5	((514/54 and cross-link\$) and hyaluronic) and comple?) and salified	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 14:58
25	3	((514/54 and cross-link\$) and hyaluronic) and comple?) and salified) and (copper or iron or zinc)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 15:33
26	22	((514/54 and cross-link\$) and hyaluronic) and (diamine or polyamine)) and sulfat?	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 15:00
27	0	((514/54 and cross-link\$) and hyaluronic) and (diamine or polyamine)) and sulfat?) and trioxide	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 15:00
28	30951	((514/54 and cross-link\$) and hyaluronic) and (diamine or polyamine)) and sulfat?) and sulfur trioxide	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 15:01

29	2	(((514/54 and cross-link\$) and hyaluronic) and (diamine or polyamine)) and sulfat?) and sulfation	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 15:04
30	0	(((polysaccharide and carboxy) and cross-link\$) and (diamine or triamine)) and hyaluronic) and sulfation	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 15:04
31	5	((536/21 and cross-link\$) and hyaluronic) and sulfation	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 15:06
32	3	(((536/21 and cross-link\$) and hyaluronic) and sulfation) and pyridine	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 15:06
33	1	((514/54 and cross-link\$) and hyaluronic) and complex?	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 15:34
34	1	(((514/54 and cross-link\$) and hyaluronic) and complex?) and (copper or zinc or iron)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 15:36
35	0	(((514/54 and cross-link\$) and hyaluronic) and complex?) and (copper or zinc or iron)) and cross-link?	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/09/23 15:36

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal623kxg

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock  
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area  
NEWS 4 Apr 09 ZDB will be removed from STN  
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB  
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS  
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER  
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available  
NEWS 9 Jun 03 New e-mail delivery for search results now available  
NEWS 10 Jun 10 MEDLINE Reload  
NEWS 11 Jun 10 PCTFULL has been reloaded  
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment  
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;  
saved answer sets no longer valid  
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY  
NEWS 15 Jul 30 NETFIRST to be removed from STN  
NEWS 16 Aug 08 CANCERLIT reload  
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN  
NEWS 18 Aug 08 NTIS has been reloaded and enhanced  
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)  
now available on STN  
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded  
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded  
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced  
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced  
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file  
NEWS 25 Sep 16 Indexing added to some pre-1967 records in CA/CAPLUS  
NEWS 26 Sep 16 CA Section Thesaurus available in CAPLUS and CA

NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,  
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),  
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 14:30:46 ON 23 SEP 2002

=> file polymers  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'BABS' ENTERED AT 14:31:14 ON 23 SEP 2002  
COPYRIGHT (c) 2002 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften  
licensed to Beilstein Chemiedaten & Software GmbH and MDL Information Systems GmbH

FILE 'CAPLUS' ENTERED AT 14:31:14 ON 23 SEP 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CBNB' ENTERED AT 14:31:14 ON 23 SEP 2002  
COPYRIGHT (c) 2002 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CEN' ENTERED AT 14:31:14 ON 23 SEP 2002  
COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 14:31:14 ON 23 SEP 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE 'DKILIT' ENTERED AT 14:31:14 ON 23 SEP 2002  
COPYRIGHT (c) 2002 FIZ Karlsruhe

FILE 'IFIPAT' ENTERED AT 14:31:14 ON 23 SEP 2002  
COPYRIGHT (C) 2002 IFI CLAIMS(R) Patent Services (IFI)

FILE 'JICST-EPLUS' ENTERED AT 14:31:14 ON 23 SEP 2002  
COPYRIGHT (C) 2002 Japan Science and Technology Corporation (JST)

FILE 'PASCAL' ENTERED AT 14:31:14 ON 23 SEP 2002  
Any reproduction or dissemination in part or in full,  
by means of any process and on any support whatsoever  
is prohibited without the prior written agreement of INIST-CNRS.  
COPYRIGHT (C) 2002 INIST-CNRS. All rights reserved.

FILE 'PLASNEWS' ENTERED AT 14:31:14 ON 23 SEP 2002  
Copyright (C) 2002 Bill Communications, Inc. (BCI)

FILE 'PROMT' ENTERED AT 14:31:14 ON 23 SEP 2002  
COPYRIGHT (C) 2002 Gale Group. All rights reserved.

FILE 'RAPRA' ENTERED AT 14:31:14 ON 23 SEP 2002  
COPYRIGHT (C) 2002 RAPRA Technology Ltd.

FILE 'SCISEARCH' ENTERED AT 14:31:14 ON 23 SEP 2002  
COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'TEXTILETECH' ENTERED AT 14:31:14 ON 23 SEP 2002  
COPYRIGHT (C) 2002 Inst. of Textile Technology

FILE 'USPATFULL' ENTERED AT 14:31:14 ON 23 SEP 2002.  
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:31:14 ON 23 SEP 2002  
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPINDEX' ENTERED AT 14:31:14 ON 23 SEP 2002  
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'WTEXTILES' ENTERED AT 14:31:14 ON 23 SEP 2002  
COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

=> s polysaccharide  
L1 218150 POLYSACCHARIDE

=> s l1 and carboxy  
L2 7277 L1 AND CARBOXY

=> s l2 and activat?  
L3 3796 L2 AND ACTIVAT?

=> s l3 and cross-link  
L4 317 L3 AND CROSS-LINK

=> s l4 and (diamine or polyamine)  
L5 76 L4 AND (DIAMINE OR POLYAMINE)

=> s l5 and hyaluroni  
L6 0 L5 AND HYALURONI

=> s l5 and hyaluronic  
L7 24 L5 AND HYALURONIC

=> dis l7 1-24 bib abs

L7 ANSWER 1 OF 24 USPATFULL  
AN 2002:235521 USPATFULL  
TI Process for ex vivo formation of mammalian bone and uses thereof  
IN Kale, Sujata, Boston, MA, UNITED STATES  
Long, Michael W., Northville, MI, UNITED STATES  
PI US 2002127711 A1 20020912  
AI US 2000-753043 A1 20001227 (9)  
DT Utility  
FS APPLICATION  
LREP Steven L. Highlander, Fulbright & Jaworski L.L.P., 600 Congress Avenue  
Suite 2400, Austin, TX, 78701  
CLMN Number of Claims: 38  
ECL Exemplary Claim: 1  
DRWN 10 Drawing Page(s)  
LN.CNT 3032  
AB The present invention concerns methods for the ex vivo formation of mammalian bone and subsequent uses of the bone. A critical and distinguishing feature of the present invention are defined tissue culture conditions and factors resulting in the formation of bone cell spheroids. The invention also provides for methods of implanting into subjects the ex vivo formed bone. Also described are methods for genetically altering the bone cell spheroids to affect bone formation, identification of candidate modulators of bone formation, and identification of genes involved in bone formation.

L7 ANSWER 2 OF 24 USPATFULL  
AN 2002:224605 USPATFULL  
TI Lipid soluble steroid prodrugs  
IN Unger, Evan C., Tucson, AZ, United States  
Shen, DeKang, Tucson, AZ, United States  
PA Imarx Therapeutics, Inc., Tucson, AZ, United States (U.S. corporation)  
PI US 6444660 B1 20020903  
AI US 2000-496761 20000203 (9)



RLI Division of Ser. No. US 1997-851780, filed on 6 May 1997, now patented,  
Pat. No. US 6090800  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Badio, Barbara P.  
LREP Woodcock Washburn LLP  
CLMN Number of Claims: 13  
ECL Exemplary Claim: 1  
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)  
LN.CNT 6452  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The present invention is directed to novel lipid soluble steroid  
prodrugs, compositions comprising steroid prodrugs, and uses of the  
same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 24 USPATFULL  
AN 2002:217089 USPATFULL  
TI Methods of using polynucleotide compositions  
IN Kabanov, Alexander V., Omaha, NE, United States  
Alakov, Valery Y., Montreal, CANADA  
Vinogradov, Serguie, Omaha, NE, United States  
PA Supratek Pharma Inc., CANADA (non-U.S. corporation)  
PI US 6440743 B1 20020827  
AI US 1999-320640 19990526 (9)  
RLI Division of Ser. No. US 1998-124943, filed on 30 Jul 1998, now patented,  
Pat. No. US 6221959 Continuation-in-part of Ser. No. US 1997-912968,  
filed on 1 Aug 1997, now patented, Pat. No. US 6353055  
Continuation-in-part of Ser. No. US 1994-342209, filed on 18 Nov 1994,  
now patented, Pat. No. US 5656611  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: McGarry, Sean; Assistant Examiner: Epps, Janet  
LREP Mathews, Collins, Shepherd & McKay, P.A.  
CLMN Number of Claims: 13  
ECL Exemplary Claim: 1  
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)  
LN.CNT 2206  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Compositions for stabilizing polynucleic acids and increasing the  
ability of polynucleic acids to cross cell membranes and act in the  
interior of a cell. In one aspect, the invention provides a  
polynucleotide complex between a polynucleotide and certain polyether  
block copolymers. The polynucleotide complex can further include a  
polycationic polymer, as well as suitable targeting molecules and  
surfactants. The invention also provides a polynucleotide complex  
between a polynucleotide and a block copolymer comprising a polyether  
block and a polycation block.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 24 USPATFULL  
AN 2002:167866 USPATFULL  
TI Acoustically active drug delivery systems  
IN Unger, Evan C., Tucson, AZ, United States  
PA Bristol-Myers Squibb Medical Imaging, Inc., Princeton, NJ, United States  
(U.S. corporation)  
PI US 6416740 B1 20020709  
AI US 1998-75343 19980511 (9)  
PRAI US 1997-46379P 19970513 (60)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Dudash, Diana; Assistant Examiner: Sharareh, Shahnam  
LREP Woodcock Washburn LLP

CLMN Number of Claims: 15  
ECL Exemplary Claim: 1  
DRWN 9 Drawing Figure(s); 9 Drawing Page(s)  
LN.CNT 5660

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to targeted therapeutic delivery systems comprising a gas or gaseous precursor filled microsphere wherein said gas or gaseous precursor filled microsphere comprises an oil, a surfactant, and a therapeutic compound. Methods of preparing the targeted therapeutic delivery systems are also embodied by the present invention which comprise processing a solution comprising an oil and a surfactant in the presence of a gaseous precursor, at a temperature below the gel to liquid crystalline phase transition temperature of the surfactant to form gas or gaseous precursor filled microsphere, and adding to said microspheres a therapeutic compound resulting in a targeted therapeutic delivery system, wherein said processing is selected from the group consisting of controlled agitation, controlled drying, and a combination thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 24 USPATFULL  
AN 2002:72457 USPATFULL  
TI SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME  
IN UNGER, EVAN C., TUCSON, AZ, UNITED STATES  
PI US 2002039594 A1 20020404  
AI US 1998-75477 A1 19980511 (9)  
PRAI US 1997-46379P 19970513 (60)  
DT Utility  
FS APPLICATION  
LREP WOODCOCK WASHBURN KURTZ, MACKIEWICZ AND NORRIS, ONE LIBERTY PLACE 46TH FLOOR, PHILADELPHIA, PA, 19103  
CLMN Number of Claims: 106  
ECL Exemplary Claim: 1  
DRWN 1 Drawing Page(s)  
LN.CNT 5207

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to a solid porous matrix comprising a solvent and a surfactant in combination with a bioactive agent. The solvent and the surfactant may, if desired, form vesicles, an agglomeration of which comprises the matrix. The composition optionally comprises a gas or a gaseous precursor. The emulsion may be dried, and subsequently reconstituted in an aqueous or organic solution.

The present invention is also directed to a method of preparing a solid porous matrix comprising combining a solvent, a surfactant, and a therapeutic to form an emulsion; and processing the emulsion by controlled drying, or controlled agitation and controlled drying to form a solid porous matrix. The resulting solid porous matrix may also comprise a gas or gaseous precursor and be added to a resuspending medium.

A method for the controlled delivery of a targeted therapeutic to a region of a patient is another embodiment of the present invention. The method comprises administering to the patient a composition having a solid porous matrix comprising a solvent, a surfactant, a therapeutic, and a gas or gaseous precursor, monitoring the composition using energy to determine the presence of the composition in the region; and releasing the therapeutic from the composition in the region using energy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 6 OF 24 USPATFULL  
AN 2002:57879 USPATFULL

TI Polynucleotide compositions for intramuscular administration  
IN Lemieux, Pierre M., Ste.-Therese, CANADA  
Kabanov, Alexander V., Omaha, NE, United States  
Alakov, Valery Y., D'Urfe, CANADA  
Vinogradov, Sergey V., Omaha, NE, United States  
PA Supratek Pharma Inc., Doryal, United States (non-U.S. corporation)  
PI US 6359054 B1 20020319  
AI US 1999-227364 19990108 (9)  
RLI Continuation-in-part of Ser. No. US 1998-124943, filed on 30 Jul 1998,  
now patented, Pat. No. US 6221959 Continuation-in-part of Ser. No. US  
1997-912968, filed on 1 Aug 1997 Continuation-in-part of Ser. No. US  
1994-342209, filed on 18 Nov 1994, now patented, Pat. No. US 5656611  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Szekely, Peter  
LREP Mathews, Collins, Shepherd & Gould, P.A.  
CLMN Number of Claims: 25  
ECL Exemplary Claim: 1  
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)  
LN.CNT 2493

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for intramuscular administration of  
polynucleotides, such as RNA, DNA, or derivatives thereof comprising  
polynucleotides and block copolymers of alkylethers. The invention also  
provides compositions and methods for stabilizing polynucleic acids and  
increasing the ability of polynucleic acids to cross cell membranes and  
act in the interior of a cell.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 7 OF 24 USPATFULL  
AN 2002:45673 USPATFULL  
TI Polynucleotide compositions  
IN Kabanov, Alexander Victorovich, Omaha, NE, United States  
Alakov, Valery Yulievich, D'Urfe, CANADA  
Vingogradov, Sergey V., Omaha, NE, United States  
PA Supratek Pharma Inc., Quebec, CANADA (non-U.S. corporation)  
PI US 6353055 B1 20020305  
AI US 1997-912968 19970801 (8)  
RLI Continuation-in-part of Ser. No. US 1994-342209, filed on 18 Nov 1994,  
now patented, Pat. No. US 5656611  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Szekely, Peter  
LREP Mathews, Collins, Shepherd & Gould, P.A.  
CLMN Number of Claims: 11  
ECL Exemplary Claim: 1  
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)  
LN.CNT 2021

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compositions for stabilizing polynucleic acids  
and increasing the ability of polynucleic acids to cross cell membranes  
and act in the interior of a cell. In one aspect, the invention provides  
a polynucleotide complex between a polynucleotide and certain polyether  
block copolymers. Preferably, the polynucleotide complex will further  
include a polycationic polymer. The compositions can further include  
suitable targeting molecules and surfactants. In another aspect, the  
invention provides a polynucleotide complex between a polynucleotide and  
a block copolymer comprising a polyether block and a polycation block.  
In yet another aspect, the invention provides polynucleotides 10 that  
have been covalently modified at their 5' or 3' end to attach a  
polyether polymer segment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 24 USPATFULL  
 AN 2002:37868 USPATFULL  
 TI Methods and compositions for sealing tissue leaks  
 IN Wilkie, James, Melrose, MA, UNITED STATES  
 Rolke, James, Fitzwilliam, NH, UNITED STATES  
 Burzio, Luis, Andover, MA, UNITED STATES  
 Tammishetti, Shekharam, Secunderabad, INDIA  
 Pendharkar, Sanyog Manohar, Oldbridge, NJ, UNITED STATES  
 PI US 2002022588 A1 20020221  
 AI US 2000-747293 A1 20001222 (9)  
 RLI Continuation-in-part of Ser. No. WO 1999-US14232, filed on 23 Jun 1999,  
 UNKNOWN  
 PRAI US 1998-90609P 19980623 (60)  
 US 2000-199469P 20000425 (60)  
 US 1999-171859P 19991222 (60)  
 DT Utility  
 FS APPLICATION  
 LREP TESTA, HURWITZ & THIBEAULT, LLP, HIGH STREET TOWER, 125 HIGH STREET,  
 BOSTON, MA, 02110  
 CLMN Number of Claims: 167  
 ECL Exemplary Claim: 1  
 DRWN No Drawings  
 LN.CNT 2885  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The invention provides methods and compositions that are useful for  
 adhering biological and/or synthetic tissues, sealing fluid and/or  
 gaseous leaks in biological and/or synthetic tissues, and preparing  
 implants useful for delivery of a bioactive molecule such as a drug, for  
 bulking applications, or for tissue prostheses. The present invention  
 also relates to bio-erodable adhesive or occluding compositions and  
 methods of using the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 9 OF 24 USPATFULL  
 AN 2002:22133 USPATFULL  
 TI Novel drosophila tumor necrosis factor class molecule ("DmTNF") and  
 variants thereof  
 IN Carroll, Pamela M., Princeton, NJ, UNITED STATES  
 Chen, Jian, Princeton, NJ, UNITED STATES  
 Ramanathan, Chandra S., Wallingford, CT, UNITED STATES  
 Xiao, Hong, Princeton Junction, NJ, UNITED STATES  
 Guan, Bo, Princeton, NJ, UNITED STATES  
 Bowen, Michael A., Lawrenceville, NJ, UNITED STATES  
 PI US 2002012968 A1 20020131  
 AI US 2001-813329 A1 20010320 (9)  
 PRAI US 2000-190816P 20000321 (60)  
 DT Utility  
 FS APPLICATION  
 LREP MARLA J MATHIAS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O  
 BOX 4000, PRINCETON, NJ, 08543-4000  
 CLMN Number of Claims: 40  
 ECL Exemplary Claim: 1  
 DRWN 18 Drawing Page(s)  
 LN.CNT 9244  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The present invention provides novel polynucleotides encoding Drosophila  
 DmTNF polypeptides, fragments and homologs thereof. The present  
 invention also is directed to novel polynucleotides encoding two  
 Drosophila DmTNF variants, DmTNFv1 and DmTNFv2 polypeptides, fragments  
 and homologs thereof. Also provided are vectors, host cells, antibodies,  
 and recombinant and synthetic methods for producing said polypeptides.  
 The invention further relates to screening methods for identifying  
 agonists and antagonists of the polynucleotides and polypeptides of the  
 present invention, in addition to methods of genetically modifying

Drosophila or cultured cells to express or mis-express DmTNF, DmTNFv1, or DmTNFv2. The invention also relates to the use of such modified insects or cells to characterize DmTNF activity, identify TNF-like genes and/or genes implicated in modulating TNF, characterize TNF signaling pathways, and/or to identify modulators of DmTNF activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 10 OF 24 USPATFULL  
AN 2001:234992 USPATFULL  
TI Nanogel networks and biological agent compositions thereof  
IN Kabanov, Alexander V., Omaha, NE, United States  
Vinogradov, Sergey V., Omaha, NE, United States  
PA Supratek Pharma, Inc., Canada (non-U.S. corporation)  
PI US 6333051 B1 20011225  
AI US 1998-146651 19980903 (9)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Riley, Jezia  
LREP Mathews, Collins, Shepherd & Gould, P.A.  
CLMN Number of Claims: 12  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 2246

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Copolymer networks having at least one cross-linked **polyamine** polymer fragment and at least one nonionic water-soluble polymer fragment, and compositions thereof, having at least one suitable biological agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 11 OF 24 USPATFULL  
AN 2001:182086 USPATFULL  
TI Novel methods of ultrasound treatment using gas or gaseous precursor-filled compositions  
IN Unger, Evan C., Tucson, AZ, United States  
PA ImaRx Pharmaceutical Corp. (U.S. corporation)  
PI US 2001031243 A1 20011018  
AI US 2001-813484 A1 20010321 (9)  
RLI Division of Ser. No. US 1997-929847, filed on 15 Sep 1997, PENDING  
DT Utility  
FS APPLICATION  
LREP Woodcock Washburn Kurtz, Mackiewicz & Norris LLP, 46th Floor, One Liberty Place, Philadelphia, PA, 19103  
CLMN Number of Claims: 34  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 6360

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention describes, among other things, the surprising discovery that gaseous precursor filled compositions are profoundly more effective as acoustically active contrast agents when they are thermally preactivated to temperatures at or above the boiling point of the instilled gaseous precursor prior to their in vivo administration to a patient. Further optimization of contrast enhancement is achieved by administering the gaseous precursor filled compositions to a patient as an infusion. Enhanced effectiveness is also achieved for ultrasound mediated targeting and drug delivery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 12 OF 24 USPATFULL  
AN 2001:167740 USPATFULL  
TI Composition for treating benign prostatic hypertrophy

IN Gokcen, Muharrem, Minneapolis, MN, United States  
Guy, Terry J., Chaska, MN, United States  
PA Immunolytics, Inc., Minneapolis, MN, United States (U.S. corporation)  
PI US 6296847 B1 20011002  
AI US 1993-154158 19931117 (8)  
RLI Continuation of Ser. No. US 1991-707662, filed on 30 May 1991, now  
abandoned Continuation of Ser. No. US 1989-429966, filed on 31 Oct 1989,  
now abandoned Continuation-in-part of Ser. No. US 1989-303809, filed on  
27 Jan. 1989, now abandoned  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Witz, Jean C.  
LREP Merchant & Gould P.C.  
CLMN Number of Claims: 31  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 3351

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a composition and method for treating benign  
prostatic hypertrophy in mammals so as to cause the dissolution and  
regression of hypertrophied prostatic tissue and thereby provide relief  
from the obstructive symptoms associated with the disease. The present  
composition preferably comprises a sterile pyrogen-free solution of the  
hydrolytic enzymes collagenase and hyaluronidase, a nonionic surfactant,  
and an antibiotic; all provided, in a pharmaceutically acceptable,  
buffered, isotonic, aqueous carrier. The present method preferably  
comprises the direct intraprostatic injection of a safe and  
therapeutically effective dose of the composition via the transurethral  
route of administration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 13 OF 24 USPATFULL  
AN 2001:144937 USPATFULL  
TI Solid matrix therapeutic compositions  
IN Unger, Evan C., Tucson, AZ, United States  
PA ImaRx Therapeutics, Inc. (U.S. corporation)  
PI US 2001018072 A1 20010830  
AI US 2001-828762 A1 20010409 (9)  
RLI Division of Ser. No. US 1998-75477, filed on 11 May 1998, PENDING  
PRAI US 1997-46379P 19970513 (60)  
DT Utility  
FS APPLICATION  
LREP Mackiewicz & Norris LLP, One Liberty Place - 46th Floor, Philadelphia,  
PA, 19103  
CLMN Number of Claims: 38  
ECL Exemplary Claim: 1  
DRWN 1 Drawing Page(s)  
LN.CNT 4899

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to a solid porous matrix comprising a  
surfactant in combination with a bioactive agent. The solid porous  
matrix may be prepared by combining a surfactant and a therapeutic,  
together with a solvent, to form an emulsion containing random  
aggregates of the surfactant and the therapeutic, and processing the  
emulsion by controlled drying, or controlled agitation and controlled  
drying to form the solid porous matrix.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 14 OF 24 USPATFULL  
AN 2001:130897 USPATFULL  
TI Prolonged release of GM-CSF  
IN Gombotz, Wayne R., Kirkland, WA, United States  
Pettit, Dean K., Seattle, WA, United States

Pankey, Susan C., Yardley, PA, United States  
PA Immunex Corporation, Seattle, WA, United States (U.S. corporation)  
PI US 6274175 B1 20010814  
AI US 1999-442370 19991117 (9)  
RLI Continuation of Ser. No. US 1998-185213, filed on 3 Nov 1998, now patented, Pat. No. US 6120807 Division of Ser. No. US 1995-542445, filed on 12 Oct 1995, now patented, Pat. No. US 5942253  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Azpuru, Carlos A  
LREP Sheiness, Diana K.  
CLMN Number of Claims: 24  
ECL Exemplary Claim: 1  
DRWN 11 Drawing Figure(s); 6 Drawing Page(s)  
LN.CNT 1524

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Formulations for controlled, prolonged release of GM-CSF have been developed. These are based on solid microparticles formed of the combination of biodegradable, synthetic polymers such as poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and copolymers thereof with excipients and drug loadings that yield zero order or first order release, or multiphasic release over a period of approximately three to twenty one days, preferably one week, when administered by injection. In the preferred embodiment, the microparticles are microspheres having diameters in the range of 10 to 60 microns, formed of a blend of PLGA having different molecular weights, most preferably 6,000, 30,000 and 41,000. Other embodiments have been developed to alter the release kinetics or the manner in which the drug is distributed in vivo. For example, in some cases a polymer is selected which elicits a mild inflammatory reaction, for example, PLGA and polyanhydrides can act as chemottractant, either due to the polymer itself or minor contaminants in the polymer, or polymers which are bioadhesive are used for transmucosal or oral delivery. In another embodiment, the GM-CSF is administered in a hydrogel which can be injected subcutaneous or at a specific site for controlled release. The microparticles or hydrogel are administered to the patient in an amount effect to stimulate proliferation of hematopoietic cells, especially white cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 15 OF 24 USPATFULL  
AN 2001:97899 USPATFULL  
TI Autocross-linked hyaluronic acid and related pharmaceutical compositions for the treatment of arthropathies  
IN Bellini, Davide, Padua, Italy  
Paparella, Annamaria, Bari, Italy  
O'Regan, Michael, Padua, Italy  
Callegaro, Lanfranco, Vicenza, Italy  
PA Fidias, S.p.A., Abano Terme, Italy (non-U.S. corporation)  
PI US 6251876 B1 20010626  
WO 9749412 19971231  
AI US 1999-202817 19990625 (9)  
WO 1997-EP3238 19970620  
19990625 PCT 371 date  
19990625 PCT 102(e) date  
PRAI IT 1996-PD163 19960621  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Peselev, Elli  
LREP Birch, Stewart, Kolasch & Birch LLP, Svensson, Leonard R.  
CLMN Number of Claims: 8  
ECL Exemplary Claim: 1,2,8  
DRWN 19 Drawing Figure(s); 17 Drawing Page(s)  
LN.CNT 1233  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compositions containing an autocross-linked form of **hyaluronic** acid as a first component in a mixture with a second component noncross-linked **hyaluronic** acid, and possibly also in combination with another pharmacologically active substance. These compositions can be used in the treatment of arthropathies due to their unique viscoelastic properties.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 16 OF 24 USPATFULL  
AN 2001:59978 USPATFULL  
TI Polynucleotide compositions  
IN Kabanov, Alexander V., Omaha, NE, United States  
Alakov, Valery Y., D'Urfe, Canada  
Vinogradov, Sergey V., Omaha, NE, United States  
PA Supratek Pharma, Inc., Montreal, Canada (non-U.S. corporation)  
PI US 6221959 B1 20010424  
AI US 1998-124943 19980730 (9)  
RLI Continuation-in-part of Ser. No. US 1998-912968, filed on 1 Aug 1998  
Continuation-in-part of Ser. No. US 1994-342209, filed on 18 Nov 1994,  
now patented, Pat. No. US 5656611  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Michl, Paul R.  
LREP Mathews, Collins, Shepherd & Gould, P.A.  
CLMN Number of Claims: 8  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 2309

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions for stabilizing polynucleic acids and increasing the ability of polynucleic acids to cross cell membranes and act in the interior of a cell. In one aspect, the invention provides a polynucleotide complex between a polynucleotide and certain polyether block copolymers. The polynucleotide complex can further include a polycationic polymer, as well as suitable targeting molecules and surfactants. The invention also provides a polynucleotide complex between a polynucleotide and a block copolymer comprising a polyether block and a polycation block.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 17 OF 24 USPATFULL  
AN 2000:124586 USPATFULL  
TI Prolonged release of GM-CSF  
IN Gombotz, Wayne, Kirkland, WA, United States  
Pettit, Dean, Seattle, WA, United States  
Pankey, Susan, Seattle, WA, United States  
PA Immunex Corporation, Seattle, WA, United States (U.S. corporation)  
PI US 6120807 20000919  
AI US 1998-185213 19981103 (9)  
RLI Division of Ser. No. US 1995-542445, filed on 12 Oct 1995, now patented,  
Pat. No. US 5942253  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Azpuru, Carlos A.  
LREP Arnall Golden & Gregory, LLP  
CLMN Number of Claims: 23  
ECL Exemplary Claim: 1  
DRWN 11 Drawing Figure(s); 6 Drawing Page(s)  
LN.CNT 1382

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Formulations for controlled, prolonged release of GM-CSF have been developed. These are based on solid microparticles formed of the combination of biodegradable, synthetic polymers such as poly(lactic



acid) (PLA), poly(glycolic acid) (PGA), and copolymers thereof with excipients and drug loadings that yield zero order or first order release, or multiphasic release over a period of approximately three to twenty one days, preferably one week, when administered by injection. In the preferred embodiment, the microparticles are microspheres having diameters in the range of 10 to 60 microns, formed of a blend of PLGA having different molecular weights, most preferably 6,000, 30,000 and 41,000. Other embodiments have been developed to alter the release kinetics or the manner in which the drug is distributed in vivo. For example, in some cases a polymer is selected which elicits a mild inflammatory reaction, for example, PLGA and polyanhydrides can act as chemoattractant, either due to the polymer itself or minor contaminants in the polymer, or polymers which are bioadhesive are used for transmucosal or oral delivery. In another embodiment, the GM-CSF is administered in a hydrogel which can be injected subcutaneous or at a specific site for controlled release. The microparticles or hydrogel are administered to the patient in an amount effect to stimulate proliferation of hematopoietic cells, especially white cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 18 OF 24 USPATFULL  
AN 2000:91955 USPATFULL  
TI Lipid soluble steroid prodrugs  
IN Unger, Evan C., Tucson, AZ, United States  
Shen, DeKang, Tucson, AZ, United States  
PA Imarx Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)  
PI US 6090800 20000718  
AI US 1997-851780 19970506 (8)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Dees, Jose' G.; Assistant Examiner: Badio, Barbara  
LREP Woodcock Washburn Kurtz Mackiewicz & Norris LLP  
CLMN Number of Claims: 10  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 6285

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to novel lipid soluble steroid prodrugs compositions comprising steroid prodrugs, and uses of the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 19 OF 24 USPATFULL  
AN 2000:87694 USPATFULL  
TI Compositions of microspheres for wound healing  
IN Ritter, Vladimir, Kiriat-Yam, Israel  
Ritter, Marina, Kiriat-Yam, Israel  
PA Polyheal Ltd., Haifa, Israel (non-U.S. corporation)  
PI US 6086863 20000711  
AI US 1998-177954 19981023 (9)  
RLI Continuation-in-part of Ser. No. US 1997-868950, filed on 4 Jun 1997, now patented, Pat. No. US 5861149  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Cintins, Marianne M.; Assistant Examiner: Kim, Vickie  
LREP Graham & James LLP  
CLMN Number of Claims: 31  
ECL Exemplary Claim: 1  
DRWN 30 Drawing Figure(s); 30 Drawing Page(s)  
LN.CNT 1659

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Therapeutic compositions of microspheres for application to wounds and/or lesions for accelerating wound healing and muscle regeneration. The microspheres are made up of non-biodegradable material having a

substantial surface charge. The therapeutic composition further includes a pharmaceutically acceptable carrier in which the microspheres are insoluble and a container for holding the composition. The therapeutic composition further contains pharmacologic agents or biologics that accelerate the wound healing process.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 20 OF 24 USPATFULL  
AN 2000:21560 USPATFULL  
TI Prodrugs comprising fluorinated amphiphiles  
IN Unger, Evan C., Tucson, AZ, United States  
PA Imarx Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)  
PI US 6028066 20000222  
AI US 1997-887215 19970702 (8)  
RLI Continuation-in-part of Ser. No. US 1997-851780, filed on 6 May 1997  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Dees, Jose' G.; Assistant Examiner: Badio, Barbara  
LREP Woodcock Washburn Kurtz Mackiewicz & Norris LLP  
CLMN Number of Claims: 8  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 6329

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention describes, inter alia, novel prodrugs comprising fluorinated amphiphiles, compositions comprising the novel prodrugs, and methods of use of the prodrugs and compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 21 OF 24 USPATFULL  
AN 1999:99401 USPATFULL  
TI Prolonged release of GM-CSF  
IN Gombotz, Wayne, Kirkland, WA, United States  
Pettit, Dean, Seattle, WA, United States  
Pankey, Susan, Seattle, WA, United States  
Lawter, James Ronald, Goshen, NY, United States  
Huang, W. James, Sommerville, NJ, United States  
PA Immunex Corporation, Seattle, WA, United States (U.S. corporation)  
American Cyanamid Company, Pearl River, NY, United States (U.S. corporation)  
PI US 5942253 19990824  
AI US 1995-542445 19951012 (8)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Azpuru, Carlos  
LREP Arnall Golden & Gregory, LLP  
CLMN Number of Claims: 27  
ECL Exemplary Claim: 1  
DRWN 11 Drawing Figure(s); 6 Drawing Page(s)  
LN.CNT 1403

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Formulations for controlled, prolonged release of GM-CSF have been developed. These are based on solid microparticles formed of the combination of biodegradable, synthetic polymers such as poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and copolymers thereof with excipients and drug loadings that yield zero order or first order release, or multiphasic release over a period of approximately three to twenty one days, preferably one week, when administered by injection. In the preferred embodiment, the microparticles are microspheres having diameters in the range of 10 to 60 microns, formed of a blend of PLGA having different molecular weights, most preferably 6,000, 30,000 and 41,000. Other embodiments have been developed to alter the release kinetics or the manner in which the drug is distributed in vivo. For

example, in some cases a polymer is selected which elicits a mild inflammatory reaction, for example, PLGA and polyanhydrides can act as chemoattractant, either due to the polymer itself or minor contaminants in the polymer, or polymers which are bioadhesive are used for transmucosal or oral delivery. In another embodiment, the GM-CSF is administered in a hydrogel which can be injected subcutaneous or at a specific site for controlled release. The microparticles or hydrogel are administered to the patient in an amount effect to stimulate proliferation of hematopoietic cells, especially white cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 22 OF 24 USPATFULL  
AN 1998:75722 USPATFULL  
TI Products comprising substrates capable of enzymatic cross-linking  
IN Cappello, Joseph, San Diego, CA, United States  
PA Protein Polymer Technologies, San Diego, CA, United States (U.S. corporation)  
PI US 5773577 19980630  
AI US 1995-397633 19950302 (8)  
RLI Continuation-in-part of Ser. No. US 1994-205518, filed on 3 Mar 1994, now abandoned  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Patterson, Jr., Charles L.; Assistant Examiner: Stole, Einar  
LREP Trecartin, Richard F. Flehr Hohbach Test Albritton & Herbert LLP  
CLMN Number of Claims: 29  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 3006

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Polymers are provided comprising protein polymers comprising blocks of repeating units and sequences comprising amino acids, individually or in defined sequences, capable of enzyme catalyzed covalent bond formation for cross-linking, as exemplified by glutamine and/or lysine reactive for FXIII catalyzed isopeptide formation or non-amino acid polymers having side chains comprising such amino acids or sequences, which may be used for preparation of articles of manufacture, particularly cross-linkable compositions. By appropriate choice of the polymer, resorbable implantable polymers may be used in internal applications for mammals as formed objects or depots.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 23 OF 24 USPATFULL  
AN 97:93905 USPATFULL  
TI Crosslinked **carboxy polysaccharides**  
IN Della Valle, Francesco, Padua, Italy  
Romeo, Aurelio, Rome, Italy  
PA Fidia, S.p.A., Abano Terme, Italy (non-U.S. corporation)  
PI US 5676964 19971014  
AI US 1995-465055 19950605 (8)  
RLI Continuation of Ser. No. US 1993-70505, filed on 1 Jun 1993 which is a continuation of Ser. No. US 1989-350919, filed on 12 May 1989, now abandoned  
PRAI IT 1988-47964 19880513  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Peseliev, Elli  
LREP Birch, Stewart, Kolasch & Birch, LLP  
CLMN Number of Claims: 65  
ECL Exemplary Claim: 1,36  
DRWN No Drawings  
LN.CNT 2523

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Inter and/or intramolecular cross-linked esters of acid polysaccharides are disclosed in which a part or all of the carboxy groups are esterified with hydroxyl groups of the same molecule and/or of different molecules of the acid polysaccharide. These inner cross-linked esters of polysaccharide acids are useful in the field of biodegradable plastic materials, to manufacture sanitary and surgical articles, in the cosmetic and pharmaceutical fields, in the food industry and in many other industrial fields.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 24 OF 24 USPATFULL  
AN 92:42541 USPATFULL  
TI Method for treating benign prostatic hypertrophy  
IN Gokcen, Muharrem, Minneapolis, MN, United States  
Guy, Terry J., Chaska, MN, United States  
PA Immunolytics, Inc., Minneapolis, MN, United States (U.S. corporation)  
PI US 5116615 19920526  
AI US 1991-707628 19910530 (7)  
RLI Continuation of Ser. No. US 1989-429966, filed on 31 Oct 1989, now abandoned which is a continuation-in-part of Ser. No. US 1989-303809, filed on 27 Jan 1989, now abandoned  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Stone, Jacqueline  
LREP Merchant, Gould, Smith, Edell, Welter & Schmidt  
CLMN Number of Claims: 19  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 3209

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a composition and method for treating benign prostatic hypertrophy in mammals so as to cause the dissolution and regression of hypertrophied prostatic tissue and thereby provide relief from the obstructive symptoms associated with the disease. The present composition preferably comprises a sterile pyrogen-free solution of the hydrolytic enzymes collagenase and hyaluronidase, a nonionic surfactant, and an antibiotic; all provided, in a pharmaceutically acceptable, buffered, isotonic, aqueous carrier. The present method preferably comprises the direct intraprostatic injection of a safe and therapeutically effective dose of the composition via the transurethral route of administration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> dis hist

(FILE 'HOME' ENTERED AT 14:30:46 ON 23 SEP 2002)

FILE 'BABS, CAPLUS, CBNB, CEN, CIN, DKILIT, IFIPAT, JICST-EPLUS, PASCAL, PLASNEWS, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL, USPAT2, WPINDEX, WTEXTILES' ENTERED AT 14:31:14 ON 23 SEP 2002

L1 218150 S POLYSACCHARIDE  
L2 7277 S L1 AND CARBOXY  
L3 3796 S L2 AND ACTIVAT?  
L4 317 S L3 AND CROSS-LINK  
L5 76 S L4 AND (DIAMINE OR POLYAMINE)  
L6 0 S L5 AND HYALURONI  
L7 24 S L5 AND HYALURONIC

=> s 17 and sulfation

L8 1 L7 AND SULFATION

=> dis 18 bib abs

L8 ANSWER 1 OF 1 USPATFULL  
AN 2002:22133 USPATFULL  
TI Novel drosophila tumor necrosis factor class molecule ("DmTNF") and  
variants thereof  
IN Carroll, Pamela M., Princeton, NJ, UNITED STATES  
Chen, Jian, Princeton, NJ, UNITED STATES  
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES  
Xiao, Hong, Princeton Junction, NJ, UNITED STATES  
Guan, Bo, Princeton, NJ, UNITED STATES  
Bowen, Michael A., Lawrenceville, NJ, UNITED STATES  
PI US 2002012968 A1 20020131  
AI US 2001-813329 A1 20010320 (9)  
PRAI US 2000-190816P 20000321 (60)  
DT Utility  
FS APPLICATION  
LREP MARLA J MATHIAS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O  
BOX 4000, PRINCETON, NJ, 08543-4000  
CLMN Number of Claims: 40  
ECL Exemplary Claim: 1  
DRWN 18 Drawing Page(s)  
LN.CNT 9244

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding Drosophila DmTNF polypeptides, fragments and homologs thereof. The present invention also is directed to novel polynucleotides encoding two Drosophila DmTNF variants, DmTNFv1 and DmTNFv2 polypeptides, fragments and homologs thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention, in addition to methods of genetically modifying Drosophila or cultured cells to express or mis-express DmTNF, DmTNFv1, or DmTNFv2. The invention also relates to the use of such modified insects or cells to characterize DmTNF activity, identify TNF-like genes and/or genes implicated in modulating TNF, characterize TNF signaling pathways, and/or to identify modulators of DmTNF activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> file chemistry  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
93.06	93.27

FULL ESTIMATED COST

FILE 'AGRICOLA' ENTERED AT 14:36:29 ON 23 SEP 2002

FILE 'ALUMINIUM' ENTERED AT 14:36:29 ON 23 SEP 2002  
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'ANABSTR' ENTERED AT 14:36:29 ON 23 SEP 2002  
COPYRIGHT (c) 2002 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'AQUIRE' ENTERED AT 14:36:29 ON 23 SEP 2002  
COPYRIGHT (C) 2002 US Environmental Protection Agency (EPA)

FILE 'BABS' ENTERED AT 14:36:29 ON 23 SEP 2002  
COPYRIGHT (c) 2002 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften  
licensed to Beilstein Chemiedaten & Software GmbH and MDL Information Systems GmbH

FILE 'BIOCOMMERCE' ENTERED AT 14:36:29 ON 23 SEP 2002  
COPYRIGHT (C) 2002 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All  
rights reserved

FILE 'BIOTECHNO' ENTERED AT 14:36:29 ON 23 SEP 2002  
COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 14:36:29 ON 23 SEP 2002  
COPYRIGHT (C) 2002 CAB INTERNATIONAL (CABI)

FILE 'CAOLD' ENTERED AT 14:36:29 ON 23 SEP 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAPLUS' ENTERED AT 14:36:29 ON 23 SEP 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CBNB' ENTERED AT 14:36:29 ON 23 SEP 2002  
COPYRIGHT (c) 2002 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CEABA-VTB' ENTERED AT 14:36:29 ON 23 SEP 2002  
COPYRIGHT (c) 2002 DECHEMA eV

FILE 'CEN' ENTERED AT 14:36:29 ON 23 SEP 2002  
COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE 'CERAB' ENTERED AT 14:36:29 ON 23 SEP 2002  
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'CIN' ENTERED AT 14:36:29 ON 23 SEP 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE 'COMPENDEX' ENTERED AT 14:36:29 ON 23 SEP 2002  
Compendex Compilation and Indexing (C) 2002  
Elsevier Engineering Information Inc (EEI). All rights reserved.  
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'CONFSCI' ENTERED AT 14:36:29 ON 23 SEP 2002  
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'COPPERLIT' ENTERED AT 14:36:29 ON 23 SEP 2002  
COPYRIGHT (C) 2002 Copper Development Association Inc. (CDA)

FILE 'CORROSION' ENTERED AT 14:36:29 ON 23 SEP 2002  
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'DKILIT' ENTERED AT 14:36:29 ON 23 SEP 2002  
COPYRIGHT (c) 2002 FIZ Karlsruhe

FILE 'ENCOMPLIT' ENTERED AT 14:36:29 ON 23 SEP 2002  
EnComplit compilation and indexing (C) 2002  
Elsevier Engineering Information Inc. All rights reserved.

FILE 'ENCOMPLIT2' ENTERED AT 14:36:29 ON 23 SEP 2002  
EnComplit2 compilation and indexing (C) 2002  
Elsevier Engineering Information Inc. All rights reserved.

FILE 'FEDRIP' ENTERED AT 14:36:29 ON 23 SEP 2002

FILE 'GENBANK' ENTERED AT 14:36:29 ON 23 SEP 2002

FILE 'INSPEC' ENTERED AT 14:36:29 ON 23 SEP 2002  
Compiled and produced by the IEE in association with FIZ KARLSRUHE

COPYRIGHT 2002 (c) INSTITUTION OF ELECTRICAL ENGINEERS (IEE)

FILE 'INSPHYS' ENTERED AT 14:36:29 ON 23 SEP 2002

Compiled and produced by the IEE in association with FIZ KARLSRUHE  
COPYRIGHT 2002 (c) INSTITUTION OF ELECTRICAL ENGINEERS (IEE)

FILE 'INVESTEXT' ENTERED AT 14:36:29 ON 23 SEP 2002

COPYRIGHT (C) 2002 Thomson Financial Services, Inc. (TFS)

FILE 'IPA' ENTERED AT 14:36:29 ON 23 SEP 2002

COPYRIGHT (C) 2002 American Society of Hospital Pharmacists (ASHP)

FILE 'JICST-EPLUS' ENTERED AT 14:36:29 ON 23 SEP 2002

COPYRIGHT (C) 2002 Japan Science and Technology Corporation (JST)

FILE 'KOSMET' ENTERED AT 14:36:29 ON 23 SEP 2002

COPYRIGHT (C) 2002 International Federation of the Societies of Cosmetics Chemists

FILE 'METADEX' ENTERED AT 14:36:29 ON 23 SEP 2002

COPYRIGHT (c) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'NAPRALERT' ENTERED AT 14:36:29 ON 23 SEP 2002

COPYRIGHT (C) 2002 Board of Trustees of the University of Illinois,  
University of Illinois at Chicago.

FILE 'NIOSH TIC' ENTERED AT 14:36:29 ON 23 SEP 2002

COPYRIGHT (C) 2002 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 14:36:29 ON 23 SEP 2002

Compiled and distributed by the NTIS, U.S. Department of Commerce.  
It contains copyrighted material.  
All rights reserved. (2002)

FILE 'PAPERCHEM2' ENTERED AT 14:36:29 ON 23 SEP 2002

Paperchem2 compilation and indexing (C) 2002  
Elsevier Engineering Information Inc. All rights reserved.

FILE 'PASCAL' ENTERED AT 14:36:29 ON 23 SEP 2002

Any reproduction or dissemination in part or in full,  
by means of any process and on any support whatsoever  
is prohibited without the prior written agreement of INIST-CNRS.  
COPYRIGHT (C) 2002 INIST-CNRS. All rights reserved.

FILE 'PROMT' ENTERED AT 14:36:29 ON 23 SEP 2002

COPYRIGHT (C) 2002 Gale Group. All rights reserved.

FILE 'RAPRA' ENTERED AT 14:36:29 ON 23 SEP 2002

COPYRIGHT (C) 2002 RAPRA Technology Ltd.

FILE 'RUSSCI' ENTERED AT 14:36:29 ON 23 SEP 2002

COPYRIGHT (C) 2002 Andrigal Ltd.

FILE 'SCISEARCH' ENTERED AT 14:36:29 ON 23 SEP 2002

COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'TULSA' ENTERED AT 14:36:29 ON 23 SEP 2002

COPYRIGHT (C) 2002 The University of Tulsa (UTULSA)

FILE 'TULSA2' ENTERED AT 14:36:29 ON 23 SEP 2002

COPYRIGHT (C) 2002 The University of Tulsa (UTULSA)

FILE 'USAN' ENTERED AT 14:36:29 ON 23 SEP 2002

COPYRIGHT (C) 2002 U.S. Pharmacopeial Convention, Inc. (USPC)

FILE 'WELDASEARCH' ENTERED AT 14:36:29 ON 23 SEP 2002

COPYRIGHT (c) 2002 The Welding Institute (TWI)

FILE 'WSCA' ENTERED AT 14:36:29 ON 23 SEP 2002  
COPYRIGHT (C) 2002 PAINT RESEARCH

=> s polysaccharide  
L9 239171 POLYSACCHARIDE

=> s l9 and carboxy  
L10 628 L9 AND CARBOXY

=> s l10 and activat?  
26 FILES SEARCHED...  
L11 40 L10 AND ACTIVAT?

=> s l11 and cross-link?  
25 FILES SEARCHED...  
L12 1 L11 AND CROSS-LINK?

=> dis l12 bib abs

L12 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS  
AN 1990:406740 CAPLUS  
DN 113:6740  
TI Preparation of crosslinked **carboxy polysaccharides** as  
biodegradable plastic materials for cosmetics and pharmaceuticals  
IN Della Valle, Francesco; Romeo, Aurelio  
PA Fidia S.p.A., Italy  
SO Eur. Pat. Appl., 37 pp.  
CODEN: EPXXDW  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 341745	A1	19891115	EP 1989-108630	19890512
	EP 341745	B1	19941214		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	WO 8910941	A1	19891116	WO 1989-EP519	19890512
	W: AU, DK, FI, HU, JP, KR				
	AU 8935747	A1	19891129	AU 1989-35747	19890512
	AU 631125	B2	19921119		
	HU 53666	A2	19901128	HU 1989-3636	19890512
	HU 210926	B	19950928		
	JP 02504163	T2	19901129	JP 1989-505458	19890512
	JP 2941324	B2	19990825		
	EP 614914	A2	19940914	EP 1994-108633	19890512
	EP 614914	A3	19941228		
	EP 614914	B1	20000816		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	ES 2064378	T3	19950201	ES 1989-108630	19890512
	IL 90274	A1	19960912	IL 1989-90274	19890512
	CA 1339122	A1	19970729	CA 1989-599557	19890512
	JP 10324701	A2	19981208	JP 1998-152832	19890512
	AT 195534	E	20000915	AT 1994-108633	19890512
	ES 2151910	T3	20010116	ES 1994-108633	19890512
	DK 9000109	A	19900312	DK 1990-109	19900112
	US 5676964	A	19971014	US 1995-465055	19950605
PRAI	IT 1988-47964	A	19880513		
	EP 1989-108630	A3	19890512		
	JP 1989-505458	A3	19890512		
	US 1989-350919	B1	19890512		
	WO 1989-EP519	A	19890512		
	US 1993-70505	A1	19930601		
AB	Inter- and/or intramol. esters of acid <b>polysaccharides</b> contg.				



carboxy functions (e.g. auto-crosslinked polysaccharides), wherein (1) a first portion or all of the carboxy groups are esterified with hydroxy groups of the same mol. and/or of different mols. of the acid polysaccharide and/or (2) a second portion of the carboxy groups are esterified with a mono- or polyvalent alcs. including various drugs (e.g. alkaloids, anesthetic, analgesic, antiinflammatory, antiviral, antibacterial, etc.) and optionally salified with an alkali or alk. earth metal, Mg, Al, or an amine including various drugs (e.g. alkaloids, peptides, antipsychotics, phenothiazine, vasoconstrictors, etc.), are prepd. by treating an acidic polysaccharide (e.g., hyaluronic acid, alginic acid, CM-cellulose, carboxymethylchitin) with an activating agent (e.g. 2-chloro-1-methylpyridinium iodide) and subjecting the resulting intermediate activated polysaccharide derivs. to heat or irradiation. These auto-crosslinked polysaccharide acids are useful in the field of biodegradable plastic materials to manuf. sanitary and surgical articles (e.g. surgical suture thread, film for artificial skin, and sponges for the medication of wounds and lesions), for pharmaceutical vehicles for controlled-release of drugs (capsules for the s.c. implantation of medicaments or microcapsules for s.c., i.m., or i.v. injection), etc.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	70.18	163.45
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.62	-0.62

STN INTERNATIONAL LOGOFF AT 14:39:42 ON 23 SEP 2002